Do analysts prefer AEMD or GCTK?

Aethlon Medical presently has a consensus target price of $1.50, indicating a potential downside of 76.74%. Given Aethlon Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe Aethlon Medical is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aethlon Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, AEMD or GCTK?

Aethlon Medical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aethlon Medical N/A N/A -$7.15M -$34.97 N/A GlucoTrack N/A N/A -$19.39M -$137.63 N/A

Is AEMD or GCTK more profitable?

Aethlon Medical's return on equity of -123.08% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets Aethlon Medical N/A -123.08% -99.28% GlucoTrack N/A -2,135.52% -290.22%

Does the media prefer AEMD or GCTK?

In the previous week, GlucoTrack had 2 more articles in the media than Aethlon Medical. MarketBeat recorded 3 mentions for GlucoTrack and 1 mentions for Aethlon Medical. Aethlon Medical's average media sentiment score of 0.75 beat GlucoTrack's score of 0.23 indicating that Aethlon Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aethlon Medical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GlucoTrack 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BJDX or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, BJDX or GCTK?

Bluejay Diagnostics is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bluejay Diagnostics N/A N/A -$6.85M -$7.11 N/A GlucoTrack N/A N/A -$19.39M -$137.63 N/A

Is BJDX or GCTK more profitable?

Bluejay Diagnostics' return on equity of -125.00% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets Bluejay Diagnostics N/A -125.00% -99.79% GlucoTrack N/A -2,135.52% -290.22%

Does the media favor BJDX or GCTK?

In the previous week, GlucoTrack had 2 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 3 mentions for GlucoTrack and 1 mentions for Bluejay Diagnostics. Bluejay Diagnostics' average media sentiment score of 0.98 beat GlucoTrack's score of 0.23 indicating that Bluejay Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bluejay Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GlucoTrack 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SONX or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SONX or GCTK more profitable?

GlucoTrack has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Sonendo's return on equity of -184.01% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets Sonendo -92.74% -184.01% -68.60% GlucoTrack N/A -2,135.52% -290.22%

Do analysts recommend ZYXI or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zynex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, ZYXI or GCTK?

Zynex has higher revenue and earnings than GlucoTrack. Zynex is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zynex $108.20M 0.04 $2.99M -$2.43 N/A GlucoTrack N/A N/A -$19.39M -$137.63 N/A

Is ZYXI or GCTK more profitable?

GlucoTrack has a net margin of 0.00% compared to Zynex's net margin of -68.35%. Zynex's return on equity of -804.30% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets Zynex -68.35% -804.30% -36.67% GlucoTrack N/A -2,135.52% -290.22%

Do analysts rate GCTK or AMIX?

Autonomix Medical has a consensus price target of $42.00, suggesting a potential upside of 1,011.11%. Given Autonomix Medical's stronger consensus rating and higher possible upside, analysts plainly believe Autonomix Medical is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Autonomix Medical 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, GCTK or AMIX?

Autonomix Medical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GlucoTrack N/A N/A -$19.39M -$137.63 N/A Autonomix Medical N/A N/A -$16.72M -$41.57 N/A

Is GCTK or AMIX more profitable?

Autonomix Medical's return on equity of -267.73% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -2,135.52% -290.22% Autonomix Medical N/A -267.73% -216.75%

Does the media refer more to GCTK or AMIX?

In the previous week, Autonomix Medical had 1 more articles in the media than GlucoTrack. MarketBeat recorded 4 mentions for Autonomix Medical and 3 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 0.23 beat Autonomix Medical's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlucoTrack 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Autonomix Medical 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

GlucoTrack (GCTK) Competitors

$1.21 -0.20 (-14.18%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.20 -0.01 (-0.83%)

As of 10/2/2026 07:56 PM Eastern

Compare

GCTK vs. AEMD, BJDX, SONX, ZYXI, and AMIX

Should you buy GlucoTrack stock or one of its competitors? GlucoTrack's main competitors and comparable companies include Aethlon Medical (AEMD), Bluejay Diagnostics (BJDX), Sonendo (SONX), Zynex (ZYXI), and Autonomix Medical (AMIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does GlucoTrack compare to Aethlon Medical?

Aethlon Medical (NASDAQ:AEMD) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

In the previous week, GlucoTrack had 2 more articles in the media than Aethlon Medical. MarketBeat recorded 3 mentions for GlucoTrack and 1 mentions for Aethlon Medical. Aethlon Medical's average media sentiment score of 0.75 beat GlucoTrack's score of 0.23 indicating that Aethlon Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aethlon Medical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GlucoTrack	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

2.0% of Aethlon Medical shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 0.6% of Aethlon Medical shares are owned by company insiders. Comparatively, 5.9% of GlucoTrack shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aethlon Medical has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

Aethlon Medical presently has a consensus target price of $1.50, indicating a potential downside of 76.74%. Given Aethlon Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe Aethlon Medical is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aethlon Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aethlon Medical's return on equity of -123.08% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aethlon Medical	N/A	-123.08%	-99.28%
GlucoTrack	N/A	-2,135.52%	-290.22%

Aethlon Medical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aethlon Medical	N/A	N/A	-$7.15M	-$34.97	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A

Summary

Aethlon Medical beats GlucoTrack on 8 of the 12 factors compared between the two stocks.

How does GlucoTrack compare to Bluejay Diagnostics?

Bluejay Diagnostics (NASDAQ:BJDX) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 6.1% of Bluejay Diagnostics shares are owned by insiders. Comparatively, 5.9% of GlucoTrack shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bluejay Diagnostics' return on equity of -125.00% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-125.00%	-99.79%
GlucoTrack	N/A	-2,135.52%	-290.22%

Bluejay Diagnostics is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A

Bluejay Diagnostics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

In the previous week, GlucoTrack had 2 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 3 mentions for GlucoTrack and 1 mentions for Bluejay Diagnostics. Bluejay Diagnostics' average media sentiment score of 0.98 beat GlucoTrack's score of 0.23 indicating that Bluejay Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bluejay Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GlucoTrack	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Bluejay Diagnostics beats GlucoTrack on 8 of the 10 factors compared between the two stocks.

How does GlucoTrack compare to Sonendo?

Sonendo (NYSE:SONX) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

GlucoTrack has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Sonendo's return on equity of -184.01% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonendo	-92.74%	-184.01%	-68.60%
GlucoTrack	N/A	-2,135.52%	-290.22%

GlucoTrack has lower revenue, but higher earnings than Sonendo. Sonendo is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonendo	$44.40M	0.09	-$60.92M	-$71.12	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, GlucoTrack had 3 more articles in the media than Sonendo. MarketBeat recorded 3 mentions for GlucoTrack and 0 mentions for Sonendo. GlucoTrack's average media sentiment score of 0.23 beat Sonendo's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the news media.

Company	Overall Sentiment
Sonendo	Neutral
GlucoTrack	Neutral

Sonendo has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

28.7% of Sonendo shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 7.9% of Sonendo shares are owned by company insiders. Comparatively, 5.9% of GlucoTrack shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Sonendo beats GlucoTrack on 7 of the 13 factors compared between the two stocks.

How does GlucoTrack compare to Zynex?

Zynex (NASDAQ:ZYXI) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zynex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GlucoTrack has a net margin of 0.00% compared to Zynex's net margin of -68.35%. Zynex's return on equity of -804.30% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zynex	-68.35%	-804.30%	-36.67%
GlucoTrack	N/A	-2,135.52%	-290.22%

In the previous week, GlucoTrack had 3 more articles in the media than Zynex. MarketBeat recorded 3 mentions for GlucoTrack and 0 mentions for Zynex. GlucoTrack's average media sentiment score of 0.23 beat Zynex's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the news media.

Company	Overall Sentiment
Zynex	Neutral
GlucoTrack	Neutral

Zynex has higher revenue and earnings than GlucoTrack. Zynex is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A

29.7% of Zynex shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 49.3% of Zynex shares are owned by insiders. Comparatively, 5.9% of GlucoTrack shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zynex has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

Summary

Zynex beats GlucoTrack on 8 of the 12 factors compared between the two stocks.

How does GlucoTrack compare to Autonomix Medical?

GlucoTrack (NASDAQ:GCTK) and Autonomix Medical (NASDAQ:AMIX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

In the previous week, Autonomix Medical had 1 more articles in the media than GlucoTrack. MarketBeat recorded 4 mentions for Autonomix Medical and 3 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 0.23 beat Autonomix Medical's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GlucoTrack	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Autonomix Medical	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Autonomix Medical's return on equity of -267.73% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-2,135.52%	-290.22%
Autonomix Medical	N/A	-267.73%	-216.75%

Autonomix Medical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A
Autonomix Medical	N/A	N/A	-$16.72M	-$41.57	N/A

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are owned by institutional investors. 5.9% of GlucoTrack shares are owned by company insiders. Comparatively, 5.5% of Autonomix Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Autonomix Medical has a consensus price target of $42.00, suggesting a potential upside of 1,011.11%. Given Autonomix Medical's stronger consensus rating and higher possible upside, analysts plainly believe Autonomix Medical is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Autonomix Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

GlucoTrack has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Autonomix Medical has a beta of -0.96, meaning that its share price is 196% less volatile than the broader market.

Summary

Autonomix Medical beats GlucoTrack on 8 of the 13 factors compared between the two stocks.

Get GlucoTrack News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GCTK vs. The Competition

Export

Metric	GlucoTrack	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$850K	$5.48B	$7.16B	$13.28B
Dividend Yield	N/A	1.81%	2.54%	17.32%
P/E Ratio	-0.01	24.90	275.66	26.04
Price / Sales	N/A	67.76	608.92	91.72
Price / Cash	N/A	32.27	78.87	52.62
Price / Book	0.03	5.73	10.93	6.31
Net Income	-$19.39M	$152.68M	$3.51B	$362.16M
7 Day Performance	-33.52%	-1.71%	-2.00%	-1.66%
1 Month Performance	-59.40%	-4.87%	-6.19%	-4.68%
1 Year Performance	-98.91%	1.30%	8.03%	1.57%

GlucoTrack Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GCTK GlucoTrack	0.4603 of 5 stars	$1.21 -14.2%	N/A	-98.9%	$850K	N/A	N/A	15	Gap Up
AEMD Aethlon Medical	1.3306 of 5 stars	$6.52 +2.2%	$1.50 -77.0%	-83.8%	$4.54M	N/A	N/A	9
BJDX Bluejay Diagnostics	1.6957 of 5 stars	$0.85 -9.0%	N/A	-86.4%	$4.20M	N/A	N/A	6	Positive News Short Interest Decrease
SONX Sonendo	N/A	$0.80 flat	N/A	N/A	$3.82M	$44.40M	N/A	250
ZYXI Zynex	N/A	$0.13 flat	N/A	N/A	$3.80M	$108.20M	N/A	770

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GCTK) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GlucoTrack (GCTK) Competitors

GCTK vs. AEMD, BJDX, SONX, ZYXI, and AMIX

How does GlucoTrack compare to Aethlon Medical?

Summary

How does GlucoTrack compare to Bluejay Diagnostics?

Summary

How does GlucoTrack compare to Sonendo?

Summary

How does GlucoTrack compare to Zynex?

Summary

How does GlucoTrack compare to Autonomix Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GlucoTrack (GCTK) Competitors

GCTK vs. AEMD, BJDX, SONX, ZYXI, and AMIX

How does GlucoTrack compare to Aethlon Medical?

Does the media prefer AEMD or GCTK?

Do insiders and institutionals believe in AEMD or GCTK?

Which has more risk & volatility, AEMD or GCTK?

Do analysts prefer AEMD or GCTK?

Is AEMD or GCTK more profitable?

Which has preferable valuation & earnings, AEMD or GCTK?

Summary

How does GlucoTrack compare to Bluejay Diagnostics?

Do insiders & institutionals believe in BJDX or GCTK?

Do analysts prefer BJDX or GCTK?

Is BJDX or GCTK more profitable?

Which has stronger earnings and valuation, BJDX or GCTK?

Which has more risk and volatility, BJDX or GCTK?

Does the media favor BJDX or GCTK?

Summary

How does GlucoTrack compare to Sonendo?

Is SONX or GCTK more profitable?

Which has stronger valuation & earnings, SONX or GCTK?

Do analysts recommend SONX or GCTK?

Does the media prefer SONX or GCTK?

Which has more volatility & risk, SONX or GCTK?

Do institutionals and insiders believe in SONX or GCTK?

Summary

How does GlucoTrack compare to Zynex?

Do analysts recommend ZYXI or GCTK?

Is ZYXI or GCTK more profitable?

Does the media prefer ZYXI or GCTK?

Which has better earnings and valuation, ZYXI or GCTK?

Do institutionals & insiders believe in ZYXI or GCTK?

Which has more volatility and risk, ZYXI or GCTK?

Summary

How does GlucoTrack compare to Autonomix Medical?

Does the media refer more to GCTK or AMIX?

Is GCTK or AMIX more profitable?

Which has stronger valuation & earnings, GCTK or AMIX?

Do institutionals & insiders hold more shares of GCTK or AMIX?

Do analysts rate GCTK or AMIX?

Which has more risk & volatility, GCTK or AMIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools